Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study

Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study

BackgroundStudies prospectively monitoring de novo donor-specific antibodies (dnDSAs) and their clinical impact are sparse. This substudy of ATHENA was initiated to evaluate the effect of everolimus (EVR) or mycophenolic acid (MPA) in combination with reduced calcineurin inhibitor (CNI, tacrolimus [...

Full description

Bibliographic Details
Main Authors: Wolfgang Arns, Aurélie Philippe, Vanessa Ditt, Ingeborg A. Hauser, Friedrich Thaiss, Claudia Sommerer, Barbara Suwelack, Duska Dragun, Jan Hillen, Christiane Schiedel, Anja Elsässer, Björn Nashan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Transplantation
Subjects:
everolimus
HLA antibodies
kidney transplant
DSA
reduced calcineurin inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/frtra.2023.1264903/full

Internet

https://www.frontiersin.org/articles/10.3389/frtra.2023.1264903/full

Similar Items